甘露醇油酸酯
甘露醇油酸酯结构式
|
常用名 | 甘露醇油酸酯 | 英文名 | 1-O-[(9Z)-9-Octadecenoyl]-D-mannopyranose |
|---|---|---|---|---|
| CAS号 | 9049-98-3 | 分子量 | 444.602 | |
| 密度 | 1.1±0.1 g/cm3 | 沸点 | 573.0±50.0 °C at 760 mmHg | |
| 分子式 | C24H44O7 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 182.6±23.6 °C |
|
Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
Vaccine 27(36) , 5020-5, (2009) To compare the ability of a native and a recombinant preparation of the major outer membrane protein of Chlamydia trachomatis mouse pneumonitis (MoPn; Ct-nMOMP and Ct-rMOMP) to protect against an intranasal (i.n.) challenge, BALB/c mice were vaccinated by the... |
|
|
Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
Vaccine 28(10) , 2236-42, (2010) A Phase 1 trial was conducted in malaria-naïve adults to evaluate the recombinant protein vaccine apical membrane antigen 1-Combination 1 (AMA1-C1) formulated in Montanide ISA 720 (SEPPIC, France), a water-in-oil adjuvant. Vaccinations were halted early due t... |
|
|
Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei.
PLoS ONE 5(8) , e12294, (2010) The Plasmodium protein Cell-traversal protein for ookinetes and sporozoites (CelTOS) plays an important role in cell traversal of host cells in both, mosquito and vertebrates, and is required for successful malaria infections. CelTOS is highly conserved among... |
|
|
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.
Clin. Vaccine Immunol. 19(10) , 1633-40, (2012) New malaria vaccines are urgently needed to improve vaccine protective efficacy. PfCelTOS is a recombinant malaria vaccine antigen that has shown protective efficacy in a small-animal challenge model when combined with a water-in-oil emulsion adjuvant (Montan... |
|
|
Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
J. Virol. Methods 167(1) , 10-6, (2010) A tetravalent dengue vaccine that can protect against all four serotypes of dengue viruses is a global priority. The host-receptor binding, multiple neutralizing epitope-containing carboxy-terminal region of the dengue envelope protein, known as domain III (E... |
|
|
CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.
Vaccine 29(45) , 7960-5, (2011) Foot-and-mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals. To prevent the spread of FMDV, inactivated virus vaccines are used to immunize animals in developing countries. However, there are safety concerns. In addition, it is diffic... |
|
|
Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
Vaccine 28(1) , 7-13, (2009) Although largely considered benign, Plasmodium vivax causes disease in nearly 75 million people each year and the available strategies are not sufficient to reduce the burden of disease, therefore pointing to vaccine development as a cost-effective control me... |
|
|
Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant
Vaccine 28(18) , 3152-8, (2010) The Plasmodium falciparum AMA-1(III) and MSP1-19 proteins have been expressed as a chimera (PfCP-2.9), adjuvanted with Montanide ISA720 and developed as a vaccine candidate tested in human. The PfCP-2.9 protein contains 18 cysteine residues that form nine int... |
|
|
Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines.
Vaccine 28(1) , 48-52, (2009) Monoclonal antibodies are used successfully in the treatment of many human disorders. However, these antibodies are expensive and have in many countries put a major strain on the health care economy. Therapeutic vaccines, directed against the same target mole... |
|
|
Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping.
Mol. Pain 6 , 56, (2010) We have previously used the rat 4 day Complete Freund's Adjuvant (CFA) model to screen compounds with potential to reduce osteoarthritic pain. The aim of this study was to identify genes altered in this model of osteoarthritic pain and use this information to... |